Kevin Kunzmann

The rare disease is caused by the mutation of one of the top risk genes for autism spectrum disorder.

The non-cancerous skin growths currently affect about 83 million US adults.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

The LiverMultiScan can quantify liver fat, and is compatible with MRI devices.

The New Zealand-based over-the-counter therapy will be available for US patients on Amazon's website in 2018.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.

Brain-derived neurotrophic factor, interleukin 6, and S100-beta concentration levels were consistent in tested TD patients.

Genentech's prophylaxis has the potential for further indications in adult and pediatric patients with hemophilia A.

In 2 different dose groups, patients reported gradual decreases in AIMS scores over 42 weeks.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

The distractive spots floating through fields of vision may have finally met their match.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

A study of over 20 years of cancer incidences show the therapy may have broken the trend.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.

ALZ-801 from Alzheon Inc. has the potential to combat an underlying pathology of AD.

Eculizumab showed efficacy for the neuromuscular disease in a randomized phase 3 study.

The most recent WMA revised declaration brings attention to possible physician burnout.

The FDA Data Monitoring Committee recommended Celgene discontinue the mongersen trials.

The approval of Magnetom Terra more than doubles the maximum MRI strength in the field.

The HVAD System, a left ventricular assist device, assists patient’s hearts in pumping and increasing blood flow through the body.

"The frequency of causing tardive dyskinesia is lesser, but it’s not zero."

The treatment is a once-daily, extended-release liquid medication, but does not require refrigeration or pharmacy reconstitution.

BRIVIACT and Aptiom were both previously approved for more particular indications in partial-onset seizure treatment.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

According to the company, several other US applications for use are still pending, and additional clinical trials for “advanced therapeutic applications” are scheduled.

Cleveland Clinic physicians weigh in on their best methods for maintaining a good doctor-patient relationship.